Market open
Savara/$SVRA
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Savara
Savara Inc is a biopharmaceutical company. It is focused on rare respiratory diseases. The company's program, molgramostim nebulizer solution (molgramostim), is an inhaled granulocyte-macrophage colony-stimulating factor in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). It has one segment specialty pharmaceuticals within the respiratory system.
Ticker
$SVRA
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
59
Website
Savara Metrics
BasicAdvanced
$610M
-
-$0.48
0.59
-
Price and volume
Market cap
$610M
Beta
0.59
52-week high
$5.34
52-week low
$2.26
Average daily volume
1.3M
Financial strength
Current ratio
13.728
Quick ratio
13.436
Long term debt to equity
15.577
Total debt to equity
15.66
Management effectiveness
Return on assets (TTM)
-33.04%
Return on equity (TTM)
-61.50%
Valuation
Price to book
3.56
Price to tangible book (TTM)
3.78
Price to free cash flow (TTM)
-6.45
Growth
Earnings per share change (TTM)
46.12%
3-year earnings per share growth (CAGR)
14.63%
What the Analysts think about Savara
Analyst Ratings
Analyst ratings (Buy, Hold, Sell) for Savara stock.
Savara Financial Performance
Income Statement
Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%
Savara Earnings Performance
Earnings per share (EPS)
Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Savara News
AllArticlesVideos
Savara Reports Fourth Quarter and Year End 2024 Financial Results and Provides Business Update
Business Wire·1 week ago
Savara Enters Into Non-Dilutive Debt Financing for up to $200M With Hercules Capital
Business Wire·1 week ago
Savara Completes Submission of the Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for MOLBREEVI* as a Treatment for Autoimmune Pulmonary Alveolar Proteinosis (aPAP)
Business Wire·1 week ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Savara stock?
Savara (SVRA) has a market cap of $610M as of April 04, 2025.
What is the P/E ratio for Savara stock?
The price to earnings (P/E) ratio for Savara (SVRA) stock is 0 as of April 04, 2025.
Does Savara stock pay dividends?
No, Savara (SVRA) stock does not pay dividends to its shareholders as of April 04, 2025.
When is the next Savara dividend payment date?
Savara (SVRA) stock does not pay dividends to its shareholders.
What is the beta indicator for Savara?
Savara (SVRA) has a beta rating of 0.59. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.